PT  - JOURNAL ARTICLE
AU  - Isaac V. Cohen
AU  - Tigran Makunts
AU  - Talar Moumedjian
AU  - Masara Issa
AU  - Ruben Abagyan
TI  - Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
AID  - 10.1101/2020.05.19.20107227
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20107227
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20107227.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20107227.full
AB  - Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to the risk of drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors declare no conflict of financial or non-financial interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study used over thirteen million AE reports available from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and its older version, Adverse Event Reporting System (AERS) data sets. At the time of the study the FAERS/AERS set contained reports from years 2000-2020, all available online at: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files Also made available here is the cleaned database "Cleaned_Data.csv" which can be used to run the supplied R code to reproduce the results. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files